Thomas VanCott, PhD - 2021 World Medical Innovation Forum
Boston
May 2–4, 2022

Thomas VanCott, PhD

Chief Technology & Strategy Officer, Catalent Cell & Gene Therapy

Dr. VanCott joined Catalent through its acquisition of Paragon Gene Therapy in 2019. Prior to Paragon he spent 14 years as the President and CEO of Advanced Bioscience Laboratories Inc. (ABL), and previously held several positions at the Henry M. Jackson Foundation for the Advancement of Military Medicine. Dr. VanCott received a doctorate in physical chemistry from the University of Virginia, and a bachelor’s degree in chemistry from Dickinson College, Carlisle, Pennsylvania.

the Future of Medicine and AI

May 11–13, 2020 | Boston, MA